What is HC Wainwright’s Estimate for CTMX Q4 Earnings?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) – Equities research analysts at HC Wainwright issued their Q4 2027 earnings per share (EPS) estimates for CytomX Therapeutics in a research note issued to investors on Monday, May 11th. HC Wainwright analyst M. Kapoor expects that the biotechnology company will post earnings of ($0.13) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for CytomX Therapeutics’ current full-year earnings is ($0.56) per share.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04. CytomX Therapeutics had a negative return on equity of 54.37% and a negative net margin of 166.40%.The business had revenue of $10.26 million during the quarter, compared to analyst estimates of $4.68 million.

Several other research analysts have also recently weighed in on the stock. Guggenheim boosted their price target on shares of CytomX Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, March 18th. Barclays increased their price objective on shares of CytomX Therapeutics from $10.00 to $16.00 and gave the company an “overweight” rating in a research note on Thursday, March 19th. Piper Sandler boosted their target price on CytomX Therapeutics from $10.00 to $12.00 and gave the stock an “overweight” rating in a research note on Monday, March 23rd. Weiss Ratings downgraded CytomX Therapeutics from a “hold (c-)” rating to a “sell (d)” rating in a research report on Thursday, March 19th. Finally, Wedbush lifted their price target on CytomX Therapeutics from $6.00 to $11.00 and gave the stock an “outperform” rating in a report on Tuesday, March 17th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $12.78.

CytomX Therapeutics Price Performance

NASDAQ CTMX opened at $3.86 on Tuesday. The company has a fifty day moving average price of $4.59 and a 200-day moving average price of $4.53. The firm has a market cap of $656.93 million, a price-to-earnings ratio of -9.41 and a beta of 2.18. CytomX Therapeutics has a 1 year low of $1.65 and a 1 year high of $8.21.

Institutional Investors Weigh In On CytomX Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN boosted its position in CytomX Therapeutics by 83.2% during the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,000 shares during the period. Farther Finance Advisors LLC bought a new position in CytomX Therapeutics in the 3rd quarter worth approximately $25,000. Mirae Asset Global Investments Co. Ltd. bought a new position in CytomX Therapeutics in the 4th quarter worth approximately $35,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new position in CytomX Therapeutics in the 3rd quarter valued at approximately $34,000. Finally, May Hill Capital LLC purchased a new position in CytomX Therapeutics in the 4th quarter valued at approximately $46,000. 67.77% of the stock is currently owned by institutional investors.

Insider Activity at CytomX Therapeutics

In other CytomX Therapeutics news, insider Yu-Waye Chu sold 21,279 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total transaction of $136,611.18. Following the completion of the transaction, the insider directly owned 189,446 shares of the company’s stock, valued at approximately $1,216,243.32. This represents a 10.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Christopher Ogden sold 19,323 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $124,053.66. Following the completion of the sale, the chief financial officer directly owned 296,948 shares of the company’s stock, valued at $1,906,406.16. This represents a 6.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 191,063 shares of company stock worth $1,226,624. 6.60% of the stock is currently owned by company insiders.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.